多次玻璃体内抗血管内皮生长因子注射对眼内压的长期影响。

Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.

机构信息

Department of Ophthalmology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea.

Department of Ophthalmology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea.

出版信息

Am J Ophthalmol. 2014 Jun;157(6):1266-1271.e1. doi: 10.1016/j.ajo.2014.02.035. Epub 2014 Feb 18.

Abstract

PURPOSE

To evaluate long-term effects of multiple intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP) in eyes with neovascular age-related macular degeneration (AMD) or retinal vein occlusion (RVO).

DESIGN

Retrospective cohort study.

METHODS

This study enrolled patients who underwent multiple (more than 3) intravitreal anti-VEGF injections and who were followed for more than 12 months after their last injection. IOP elevation was defined as an increase of 5 mm Hg over the baseline measurement on 2 consecutive visits. The frequency of IOP elevation was determined. A hazard ratio of each putative risk factor for IOP elevation was calculated using the Cox proportional hazard model for all participants, incorporating underlying disease as a covariate, as well as for each cohort.

RESULTS

Included in the analysis were 629 eyes with neovascular AMD and 95 eyes with RVO. Twenty eyes with neovascular AMD (3.0%) and 7 eyes with RVO (7.4%) experienced IOP elevation after multiple anti-VEGF injections, with an overall incidence of 3.7%. In the Cox proportional hazard analysis of total participants, a diagnosis of RVO (3.424, P = 0.005), a history of glaucoma (8.441, P = 0.001), and low baseline IOP (0.865, P = 0.040) were all significant risk factors for IOP elevation after multiple anti-VEGF injections.

CONCLUSION

A history of multiple intravitreal anti-VEGF injections was not a significant risk factor for IOP elevation in our study. IOP elevation was more common in eyes with RVO than with AMD after anti-VEGF injection.

摘要

目的

评估多次玻璃体内抗血管内皮生长因子(VEGF)注射对新生血管性年龄相关性黄斑变性(AMD)或视网膜静脉阻塞(RVO)患者眼内压(IOP)的长期影响。

设计

回顾性队列研究。

方法

本研究纳入了接受多次(超过 3 次)玻璃体内抗 VEGF 注射且末次注射后随访超过 12 个月的患者。IOP 升高定义为连续 2 次就诊时比基线测量值升高 5mmHg。确定 IOP 升高的频率。使用 Cox 比例风险模型计算每个潜在危险因素的风险比,该模型将基础疾病作为协变量纳入所有参与者,以及每个队列。

结果

纳入分析的有 629 只患新生血管性 AMD 的眼和 95 只患 RVO 的眼。20 只患新生血管性 AMD 的眼(3.0%)和 7 只患 RVO 的眼(7.4%)在多次抗 VEGF 注射后出现 IOP 升高,总体发生率为 3.7%。在总参与者的 Cox 比例风险分析中,RVO 诊断(3.424,P=0.005)、青光眼病史(8.441,P=0.001)和较低的基线 IOP(0.865,P=0.040)均为多次抗 VEGF 注射后 IOP 升高的显著危险因素。

结论

在本研究中,多次玻璃体内抗 VEGF 注射史不是 IOP 升高的显著危险因素。与 AMD 相比,RVO 眼在抗 VEGF 注射后更常见 IOP 升高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索